Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors
Gespeichert in:
| Veröffentlicht in: | Haemophilia : the official journal of the World Federation of Hemophilia 2023-01, Vol.29 (1), p.348-351 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 351 |
|---|---|
| container_issue | 1 |
| container_start_page | 348 |
| container_title | Haemophilia : the official journal of the World Federation of Hemophilia |
| container_volume | 29 |
| creator | Dubé, Evemie Merlen, Clémence Bonnefoy, Arnaud Pilon, Josie Zourikian, Nichan Gauthier, Julie St‐Louis, Jean Rivard, Georges‐Étienne |
| description | |
| doi_str_mv | 10.1111/hae.14685 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2730643709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2730643709</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2835-8a943af0768d283c6afadc25ce017135a41837ee38d93ca9f6d3637c1677a9573</originalsourceid><addsrcrecordid>eNp1kLtOwzAUhi0EoqUw8ALIEgsMae04sR22qioUCYkBmCPHcYir3IiTVuXpOSWFAQkvvn36zjk_QpeUTCmsWa7MlAZchkdoTBkPPT-k_Hh_DqknfcpH6My5NSGU-YSfohHjjIZM8jHSL1vb6dxW77irsSmttp99qZI7PMdNW7vG6M5uDHZ9uzG2KFSl4dL16Q7bCkPhsm5yW1gFvOuTNeAOgzKH79wmtqtbd45OMlU4c3HYJ-jtfvm6WHlPzw-Pi_mTp33JQk-qKGAqI4LLFB40V5lKtR9qQ6iAUVRAJRPGMJlGTKso4ynMITTlQqgoFGyCbgYvNP7RG9fFpXXa7Js2de9iXzDCAyZIBOj1H3Rd920F3QHFJfUjH9wTdDtQGpJwrcniprWlancxJfE--RgCiL-TB_bqYOyT0qS_5E_UAMwGYGsLs_vfFK_my0H5BQSLjMY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2768129236</pqid></control><display><type>article</type><title>Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Dubé, Evemie ; Merlen, Clémence ; Bonnefoy, Arnaud ; Pilon, Josie ; Zourikian, Nichan ; Gauthier, Julie ; St‐Louis, Jean ; Rivard, Georges‐Étienne</creator><creatorcontrib>Dubé, Evemie ; Merlen, Clémence ; Bonnefoy, Arnaud ; Pilon, Josie ; Zourikian, Nichan ; Gauthier, Julie ; St‐Louis, Jean ; Rivard, Georges‐Étienne</creatorcontrib><identifier>ISSN: 1351-8216</identifier><identifier>EISSN: 1365-2516</identifier><identifier>DOI: 10.1111/hae.14685</identifier><identifier>PMID: 36315386</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antibodies, Bispecific - pharmacology ; Antibodies, Bispecific - therapeutic use ; Antibodies, Monoclonal, Humanized - pharmacology ; Antibodies, Monoclonal, Humanized - therapeutic use ; Factor VIII - therapeutic use ; Hemophilia ; Hemophilia A - drug therapy ; Humans ; Prospective Studies</subject><ispartof>Haemophilia : the official journal of the World Federation of Hemophilia, 2023-01, Vol.29 (1), p.348-351</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><rights>2023 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2835-8a943af0768d283c6afadc25ce017135a41837ee38d93ca9f6d3637c1677a9573</citedby><cites>FETCH-LOGICAL-c2835-8a943af0768d283c6afadc25ce017135a41837ee38d93ca9f6d3637c1677a9573</cites><orcidid>0000-0003-1183-533X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhae.14685$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhae.14685$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36315386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dubé, Evemie</creatorcontrib><creatorcontrib>Merlen, Clémence</creatorcontrib><creatorcontrib>Bonnefoy, Arnaud</creatorcontrib><creatorcontrib>Pilon, Josie</creatorcontrib><creatorcontrib>Zourikian, Nichan</creatorcontrib><creatorcontrib>Gauthier, Julie</creatorcontrib><creatorcontrib>St‐Louis, Jean</creatorcontrib><creatorcontrib>Rivard, Georges‐Étienne</creatorcontrib><title>Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors</title><title>Haemophilia : the official journal of the World Federation of Hemophilia</title><addtitle>Haemophilia</addtitle><subject>Antibodies, Bispecific - pharmacology</subject><subject>Antibodies, Bispecific - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Factor VIII - therapeutic use</subject><subject>Hemophilia</subject><subject>Hemophilia A - drug therapy</subject><subject>Humans</subject><subject>Prospective Studies</subject><issn>1351-8216</issn><issn>1365-2516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOwzAUhi0EoqUw8ALIEgsMae04sR22qioUCYkBmCPHcYir3IiTVuXpOSWFAQkvvn36zjk_QpeUTCmsWa7MlAZchkdoTBkPPT-k_Hh_DqknfcpH6My5NSGU-YSfohHjjIZM8jHSL1vb6dxW77irsSmttp99qZI7PMdNW7vG6M5uDHZ9uzG2KFSl4dL16Q7bCkPhsm5yW1gFvOuTNeAOgzKH79wmtqtbd45OMlU4c3HYJ-jtfvm6WHlPzw-Pi_mTp33JQk-qKGAqI4LLFB40V5lKtR9qQ6iAUVRAJRPGMJlGTKso4ynMITTlQqgoFGyCbgYvNP7RG9fFpXXa7Js2de9iXzDCAyZIBOj1H3Rd920F3QHFJfUjH9wTdDtQGpJwrcniprWlancxJfE--RgCiL-TB_bqYOyT0qS_5E_UAMwGYGsLs_vfFK_my0H5BQSLjMY</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Dubé, Evemie</creator><creator>Merlen, Clémence</creator><creator>Bonnefoy, Arnaud</creator><creator>Pilon, Josie</creator><creator>Zourikian, Nichan</creator><creator>Gauthier, Julie</creator><creator>St‐Louis, Jean</creator><creator>Rivard, Georges‐Étienne</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1183-533X</orcidid></search><sort><creationdate>202301</creationdate><title>Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors</title><author>Dubé, Evemie ; Merlen, Clémence ; Bonnefoy, Arnaud ; Pilon, Josie ; Zourikian, Nichan ; Gauthier, Julie ; St‐Louis, Jean ; Rivard, Georges‐Étienne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2835-8a943af0768d283c6afadc25ce017135a41837ee38d93ca9f6d3637c1677a9573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Bispecific - pharmacology</topic><topic>Antibodies, Bispecific - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Factor VIII - therapeutic use</topic><topic>Hemophilia</topic><topic>Hemophilia A - drug therapy</topic><topic>Humans</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dubé, Evemie</creatorcontrib><creatorcontrib>Merlen, Clémence</creatorcontrib><creatorcontrib>Bonnefoy, Arnaud</creatorcontrib><creatorcontrib>Pilon, Josie</creatorcontrib><creatorcontrib>Zourikian, Nichan</creatorcontrib><creatorcontrib>Gauthier, Julie</creatorcontrib><creatorcontrib>St‐Louis, Jean</creatorcontrib><creatorcontrib>Rivard, Georges‐Étienne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dubé, Evemie</au><au>Merlen, Clémence</au><au>Bonnefoy, Arnaud</au><au>Pilon, Josie</au><au>Zourikian, Nichan</au><au>Gauthier, Julie</au><au>St‐Louis, Jean</au><au>Rivard, Georges‐Étienne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors</atitle><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle><addtitle>Haemophilia</addtitle><date>2023-01</date><risdate>2023</risdate><volume>29</volume><issue>1</issue><spage>348</spage><epage>351</epage><pages>348-351</pages><issn>1351-8216</issn><eissn>1365-2516</eissn><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36315386</pmid><doi>10.1111/hae.14685</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1183-533X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-8216 |
| ispartof | Haemophilia : the official journal of the World Federation of Hemophilia, 2023-01, Vol.29 (1), p.348-351 |
| issn | 1351-8216 1365-2516 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2730643709 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies, Bispecific - pharmacology Antibodies, Bispecific - therapeutic use Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Factor VIII - therapeutic use Hemophilia Hemophilia A - drug therapy Humans Prospective Studies |
| title | Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A29%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Switching%20to%20emicizumab:%20A%20prospective%20surveillance%20study%20in%20haemophilia%20A%20subjects%20with%20inhibitors&rft.jtitle=Haemophilia%20:%20the%20official%20journal%20of%20the%20World%20Federation%20of%20Hemophilia&rft.au=Dub%C3%A9,%20Evemie&rft.date=2023-01&rft.volume=29&rft.issue=1&rft.spage=348&rft.epage=351&rft.pages=348-351&rft.issn=1351-8216&rft.eissn=1365-2516&rft_id=info:doi/10.1111/hae.14685&rft_dat=%3Cproquest_cross%3E2730643709%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2768129236&rft_id=info:pmid/36315386&rfr_iscdi=true |